These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2106770)

  • 41. The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis.
    Tsao NW; Bansback NJ; Shojania K; Marra CA
    Best Pract Res Clin Rheumatol; 2012 Oct; 26(5):659-76. PubMed ID: 23218430
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK.
    Guest JF; Davie AM; Clegg JP
    Curr Med Res Opin; 2005 Jun; 21(6):817-26. PubMed ID: 15969881
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone.
    Korthals-de Bos I; Van Tulder M; Boers M; Verhoeven AC; Adèr HJ; Bibo J; Boonen A; Van Der Linden S
    J Rheumatol; 2004 Sep; 31(9):1709-16. PubMed ID: 15338488
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The application of economic evaluation methods in the chronic pain medicine literature.
    Vetter TR
    Anesth Analg; 2007 Jul; 105(1):114-8. PubMed ID: 17578966
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Economic evaluation of drugs in peripheral vascular disease and stroke.
    Drummond M; Davies L
    J Cardiovasc Pharmacol; 1994; 23 Suppl 3():S4-7. PubMed ID: 7517476
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
    Davies A; Cifaldi MA; Segurado OG; Weisman MH
    J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Golimumab for the treatment of psoriatic arthritis.
    Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
    Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.
    Kobelt G; Eberhardt K; Geborek P
    Ann Rheum Dis; 2004 Jan; 63(1):4-10. PubMed ID: 14672883
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies.
    Huelin R; Pokora T; Foster TS; Mould JF
    Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):505-23. PubMed ID: 22971036
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Shared care or nurse consultations as an alternative to rheumatologist follow-up for rheumatoid arthritis (RA) outpatients with stable low disease-activity RA: cost-effectiveness based on a 2-year randomized trial.
    Sørensen J; Primdahl J; Horn HC; Hørslev-Petersen K
    Scand J Rheumatol; 2015; 44(1):13-21. PubMed ID: 25380077
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Sheffield rheumatoid arthritis health economic model.
    Tosh J; Brennan A; Wailoo A; Bansback N
    Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv26-31. PubMed ID: 21859702
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Economic evaluation of adult rehabilitation: a systematic review and meta-analysis of randomized controlled trials in a variety of settings.
    Brusco NK; Taylor NF; Watts JJ; Shields N
    Arch Phys Med Rehabil; 2014 Jan; 95(1):94-116.e4. PubMed ID: 23562414
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial.
    von Scheele B; Peña B; Wong J; Niculescu L
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii53-9. PubMed ID: 14585918
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Critical analysis of economic tools and economic measurement applied to rheumatoid arthritis.
    Her M; Kavanaugh A
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S107-11. PubMed ID: 23078839
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Maetzel A; Strand V; Tugwell P; Wells G; Bombardier C
    Arthritis Rheum; 2002 Dec; 47(6):655-61. PubMed ID: 12522841
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies.
    O'Hagan A; Stevens JW
    Stat Methods Med Res; 2002 Dec; 11(6):469-90. PubMed ID: 12516985
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advantages and limitations of utility assessment methods in rheumatoid arthritis.
    Beresniak A; Russell AS; Haraoui B; Bessette L; Bombardier C; Duru G
    J Rheumatol; 2007 Nov; 34(11):2193-200. PubMed ID: 17937471
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M
    Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study].
    Haldemann R; Lüscher TF; Szucs TD
    Praxis (Bern 1994); 2001 Mar; 90(13):539-45. PubMed ID: 11550619
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.
    Soini EJ; Hallinen TA; Puolakka K; Vihervaara V; Kauppi MJ
    J Med Econ; 2012; 15(2):340-51. PubMed ID: 22168785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.